Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| M | IH(P) | M | Purified | Monoclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | MABN1837 |
| Description | Anti-AGE Antibody, Carboxy-Methyl Lysine Antibody, clone 6C7 |
| Alternate Names |
|
| Background Information | Chronic accumulation of Advanced Glycation End products (AGEs) is a common feature during aging, hyperlipidemia, and diabetes and affects function of proteins, lipids, and DNA. Although formation of AGE products is considered to be predominantly an endogenous process, certain external factors, such as some dietary products and smoking can increase the level of AGE in tissues. Under certain conditions glucose may form covalent adducts with the plasma proteins through the process of glycation. Glycation is a non-enzymatic reaction of reducing carbohydrates with lysine side chains and N-terminal amino groups of proteins. The term AGE often refers to non-reactive terminal products, such as N- carboxymethyllysine (CML) as well as reactive precursors, such as methylglyoxal (mg). CML is an AGE product that is usually found on proteins and lipids as a result of oxidative stress and chemical glycation. Excessive glycation can disrupt protein function by altering enzyme activity, receptor function, and molecular conformation. Protein glycation and subsequent formation of AGE products contributes to the pathogenesis of diabetes-related complications, such as retinopathy, nephropathy, and neuropathy. Higher levels of CML have been linked to greater hip fracture risk in older adults, independent of bone mineral density. AGE products interact with a variety of cell-surface AGE-binding receptors (RAGE) that results in their endocytosis and degradation. It can also generate pro-oxidant and pro-inflammatory events in cells. AGE products could also contribute to the development or worsening of many degenerative diseases, including Alzheimers disease. (Ref.: Cai, W., et Al. (2002). Mol. Med 8 (7): 337-346; Barzilay, JI et Al (2014). J. Bone Miner. Res. 29(5):1061-1066). |
| Product Information | |
|---|---|
| Format | Purified |
| Presentation | Purified mouse monoclonal antibody IgG2a in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mm NaCl with 0.05% sodium azide. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-AGE, Carboxy-Methyl Lysine, clone 6C7, Cat. No. MABN1837, is a highly specific mouse monoclonal antibody, that targets Carboxy-Methyl Lysine (CML) modified proteins and has been tested in Immunohistochemistry (Paraffin). |
| Key Applications |
|
| Biological Information | |
|---|---|
| Immunogen | Carboxymethyl Lysine modified Keyhole Limpet Hemocyanin (KLH). |
| Clone | 6C7 |
| Concentration | Please refer to lot specific datasheet. |
| Host | Mouse |
| Specificity | Clone 6C7 specifically reacts with carboxymethyl lysine modified proteins. |
| Isotype | IgG2aκ |
| Species Reactivity |
|
| Species Reactivity Note | Mouse. Predicted to react with Human and Rat. |
| Antibody Type | Monoclonal Antibody |
| Purification Method | Protein g purified |
| Product Usage Statements | |
|---|---|
| Quality Assurance | Evaluated by Immunohistochemistry in mouse kidney tissue. Immunohistochemistry Analysis: A 1:50 dilution of this antibody detected AGE, Carboxy-Methyl Lysine in kidney tissue of mice fed high AGE diets. |
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at 2-8°C from date of receipt. |
| Packaging Information | |
|---|---|
| Material Size | 100 μg |